Viewing Study NCT01503502

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:39 AM
Ignite Modification Date: 2026-03-04 @ 10:43 PM
Study NCT ID: NCT01503502
Status: UNKNOWN
Last Update Posted: 2013-04-10
First Post: 2012-01-01
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Myelogenous Leukemia, Chronic View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Myelogenous Leukemia View
None chronce View
None Philadelphia Chromosome Positive View
None Flumatinib View